1. Introduction

Decentralized Trial Governance (DTG) refers to the legal, regulatory, ethical and institutional framework governing clinical trials conducted through decentralized methods rather than exclusively at traditional hospitals, research institutions or centralized clinical trial sites.

In conventional clinical trials, participants generally visit designated hospitals or research centres for recruitment, medical examinations, administration of investigational medicines, monitoring and collection of clinical data.

In decentralized trials, these activities may take place through a combination of:

Participants' homes and community healthcare facilities.

Telemedicine consultations and remote medical supervision.

Wearable devices and digital health-monitoring technologies.

Electronic informed-consent systems.

Home delivery of investigational medicinal products.

Remote laboratory testing and sample collection.

Mobile healthcare professionals.

Electronic patient-reported outcome systems.

Decentralized Trial Governance determines who has legal authority, responsibility and accountability when clinical research activities are distributed across different locations, professionals, technologies and institutions.

Its central objective is to protect participants' rights, ensure scientific reliability, maintain data integrity and establish clear legal responsibility for research-related harm.

2. Legal and regulatory foundations

Decentralized Trial Governance does not create a separate exemption from ordinary clinical-trial regulation. It applies existing clinical-trial standards to a distributed research environment.

A. Indian legal framework

India's decentralized clinical trial governance is primarily influenced by the following laws and regulatory instruments.

1. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 provide the principal regulatory framework for clinical trials involving new drugs and investigational new drugs.

Important areas include:

Permission and registration of clinical trials.

Responsibilities of sponsors and investigators.

Ethics Committee approval and oversight.

Informed consent requirements.

Medical management and compensation for trial-related injury or death.

Reporting of serious adverse events.

Regulatory inspection and compliance.

In decentralized trials, these requirements must continue to be satisfied even when participants receive trial-related services at home or through local healthcare professionals.

2. Drugs and Cosmetics Act, 1940

The Act provides the statutory foundation for regulating drugs, including investigational products. It supports regulatory supervision of clinical investigations and the protection of participants against unsafe or unauthorized drug-related activities.

3. Digital Personal Data Protection Act, 2023

Decentralized trials generate significant quantities of personal data through wearable devices, telemedicine, electronic health records and remote monitoring.

The data-protection framework is relevant to:

Lawful processing of personal data.

Participant information and consent where applicable.

Security safeguards.

Data sharing with sponsors and technology providers.

Retention and deletion obligations.

Handling of personal-data breaches.

Clinical-trial data governance must also account for applicable research, medical confidentiality and other sector-specific requirements. Data protection should not be treated as merely a technical IT responsibility.

4. ICMR National Ethical Guidelines, 2017

The Indian Council of Medical Research's ethical guidelines establish important principles for biomedical and health research involving human participants.

These include:

Respect for human dignity.

Voluntary informed consent.

Beneficence and non-maleficence.

Justice and fair participant selection.

Privacy and confidentiality.

Independent ethical review.

Protection of vulnerable populations.

5. Telemedicine Practice Guidelines, 2020

These guidelines are relevant when investigators or healthcare professionals conduct remote consultations as part of trial activities.

Telemedicine does not remove professional duties concerning appropriate clinical assessment, patient confidentiality, documentation and referral for physical examination when necessary.

3. Major principles of decentralized trial governance

A. Distributed institutional accountability

Traditional trials generally operate through a defined institutional structure. Decentralized trials involve multiple independent actors.

For example:

Pharmaceutical sponsors design and finance research.

Principal investigators supervise clinical conduct.

Local healthcare professionals perform delegated procedures.

Technology companies maintain digital platforms.

Laboratories process biological samples.

Delivery providers transport investigational medicines.

Ethics Committees monitor participant protection.

The legal challenge is determining responsibility when multiple actors participate in a single research activity.

A sponsor cannot automatically escape its regulatory responsibilities by outsourcing clinical activities to third-party organizations.

Similarly, investigators must maintain appropriate supervision over delegated clinical activities.

Governance requirement: Every decentralized trial should have a written responsibility-allocation framework identifying the functions, qualifications, reporting obligations and accountability of each participant in the research network.

B. Decentralized informed consent

Informed consent is one of the most important components of decentralized trial governance.

Consent may be obtained electronically or through a remote video consultation, where permitted by the applicable regulatory framework.

However, electronic acceptance of a document does not automatically establish valid informed consent.

A proper process should ensure:

The participant receives understandable information about the trial.

The investigator explains foreseeable risks and potential benefits.

The participant has an opportunity to ask questions.

Participation is voluntary.

The participant understands the right to withdraw.

Consent is properly documented and preserved.

Special attention is necessary where participants have limited digital literacy, language difficulties, disabilities or impaired decision-making capacity.

C. Remote patient monitoring

Remote patient monitoring involves collecting information through wearable devices, mobile applications, digital questionnaires and connected medical equipment.

Examples include:

Blood-pressure monitoring.

Heart-rate monitoring.

Glucose monitoring.

Sleep monitoring.

Neurological activity monitoring.

Medication-adherence monitoring.

This creates several governance questions:

Who verifies the accuracy of the device?

Who reviews abnormal results?

How quickly must investigators respond?

Who is responsible if an emergency alert is ignored?

Can a participant challenge inaccurate digital records?

A decentralized trial should establish an emergency-response protocol, data-validation procedures and clear clinical escalation responsibilities.

D. Investigational medicinal product management

In conventional clinical trials, medicines are generally administered or distributed through designated research facilities.

Decentralized trials may involve direct delivery of investigational medicinal products to participants.

This creates legal concerns involving:

Storage and temperature control.

Transportation and packaging.

Identity verification.

Product traceability.

Administration instructions.

Adherence monitoring.

Drug accountability.

Return and disposal of unused medicines.

The sponsor and investigator must ensure that decentralization does not undermine investigational-product safety or accountability.

E. Ethics Committee governance

Ethics Committees must assess whether decentralized research methods adequately protect participants.

Their responsibilities include examining:

Remote recruitment procedures.

Electronic consent systems.

Home-based medical procedures.

Participant privacy.

Technology-related risks.

Emergency medical arrangements.

Data-sharing agreements.

Vulnerable participant protection.

A trial protocol should clearly identify the locations and methods through which research activities will be conducted.

F. Digital evidence and data integrity

Decentralized trials create evidentiary challenges because research data may originate from different devices, institutions and geographic locations.

For example, a participant's wearable device may record an abnormal heart rhythm. The information may then pass through a software platform, a cloud server and an investigator's dashboard.

If the data is altered, delayed, lost or incorrectly interpreted, determining responsibility becomes difficult.

Good governance therefore requires:

Reliable electronic audit trails.

Authentication and access controls.

Data encryption.

Device validation.

Accurate timestamps.

Version control.

Backup and recovery procedures.

Inspection-ready records.

Digital records should be attributable, contemporaneous, original or appropriately verified, accurate and complete.

4. Important judicial decisions and case laws

There is currently no widely established Indian Supreme Court judgment specifically deciding the legality of a fully decentralized clinical trial. However, several important judgments establish principles that directly influence decentralized trial governance.

1. Swasthya Adhikar Manch, Indore v. Union of India (2013)

Citation: W.P. (C) No. 33 of 2012, Supreme Court of India.

This is one of the most important Indian decisions concerning clinical-trial regulation and participant protection.

The petition raised concerns about unethical clinical trials, participant deaths, serious adverse effects and inadequate compensation.

The Supreme Court examined the need for stronger regulatory supervision and safeguards in clinical research.

Legal principles:

Clinical-trial participants require effective protection.

Regulatory authorities must ensure appropriate oversight.

Risk-benefit assessment is essential.

Compensation mechanisms must be meaningful.

Informed consent must be properly documented.

The Court also dealt with audiovisual recording of informed-consent procedures and preservation of documentation.

Relevance to decentralized trials: Remote consent, electronic records and home-based research must provide reliable evidence that participants genuinely understood and voluntarily accepted the research risks.

2013 Supreme(SC) 1309+1

2. Swasthya Adhikar Manch v. Ministry of Health and Family Welfare (2012)

Citation: W.P. (C) No. 33 of 2012, Supreme Court of India, order dated 8 October 2012.

The Supreme Court sought information concerning clinical-trial approvals, deaths, serious adverse effects and compensation paid to participants or their families.

The case emphasized transparency and accountability in clinical research.

Legal principles:

Government authorities must supervise clinical research.

Clinical-trial deaths and serious injuries require regulatory attention.

Compensation information is important for public accountability.

Participant protection cannot be subordinated to commercial research interests.

Relevance: Decentralized trials must have effective mechanisms for reporting adverse events across different locations. The sponsor cannot allow fragmented reporting systems to create gaps in regulatory oversight.

2012 Supreme(SC) 2612

3. Samira Kohli v. Dr. Prabha Manchanda (2008)

Citation: (2008) 2 SCC 1.

The Supreme Court considered the validity of medical consent when a doctor performed surgery beyond the procedure authorized by the patient.

The Court emphasized that consent must be voluntary, competent and based on adequate information.

Consent for one medical procedure does not automatically authorize a different procedure.

Legal principles:

Consent must be genuine and valid.

A patient has the right to decide what happens to their body.

Consent cannot ordinarily be expanded beyond the procedure authorized.

Medical necessity may justify an additional procedure in narrowly defined emergency circumstances.

Relevance: In decentralized clinical trials, participants must understand the specific procedures, monitoring technologies, data collection and interventions to which they are consenting. General acceptance of a digital platform cannot replace appropriate consent for trial participation.

Indian Kanoon+1

4. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1.

The Supreme Court recognized privacy as a fundamental right under Article 21 of the Indian Constitution.

The judgment is particularly important for decentralized clinical trials because such trials may continuously collect sensitive personal information.

Legal principles:

Privacy is constitutionally protected.

Informational privacy is an essential aspect of individual autonomy.

Collection and processing of personal information require appropriate legal justification.

State interference with privacy must satisfy constitutional standards of legality, legitimate purpose and proportionality.

Relevance: Continuous monitoring through wearable devices, genetic-data collection, remote neurological measurements and cloud-based medical records can create substantial privacy risks.

The judgment provides a constitutional foundation for protecting participants against unjustified collection, disclosure and use of their personal information.

5. Jacob Mathew v. State of Punjab (2005)

Citation: (2005) 6 SCC 1.

The Supreme Court considered the legal standards governing medical negligence and professional responsibility.

It discussed the standard of reasonable professional care and the circumstances in which medical professionals may incur negligence liability.

Legal principles:

Medical professionals must exercise reasonable skill and care.

Professional negligence requires an appropriate legal assessment of the conduct.

Criminal medical negligence requires a higher threshold than ordinary civil negligence.

Relevance: Where a local healthcare professional performs a trial-related procedure, responsibility may arise if the professional fails to meet the applicable standard of care. Remote supervision does not automatically eliminate the duties of the professional physically attending the participant.

6. Indian Medical Association v. V.P. Shantha (1995)

Citation: (1995) 6 SCC 651.

The Supreme Court examined the applicability of consumer-protection legislation to medical services.

The decision is relevant to understanding the potential civil consequences of deficiencies in healthcare services.

Relevance: Where trial participants receive healthcare services involving payment or consideration, questions concerning consumer remedies and deficient services may arise depending on the facts and applicable law. Clinical-trial compensation and regulatory remedies must nevertheless be separately examined.

5. International judicial and regulatory developments

Decentralized trial governance is also influenced by international research-ethics and regulatory standards.

A. Grimes v. Kennedy Krieger Institute (2001)

Citation: 782 A.2d 807 (Md. 2001).

The Maryland Court of Appeals examined ethical and legal issues arising from research involving children exposed to environmental lead.

The litigation raised important questions concerning research risks, parental consent and the protection of vulnerable participants.

Relevance: Decentralized trials involving children, elderly persons or individuals with limited decision-making capacity require additional safeguards. Digital convenience cannot justify reduced protection for vulnerable populations.

B. FDA Guidance on Decentralized Clinical Trials (2024)

The United States Food and Drug Administration issued its final guidance, Conducting Clinical Trials With Decentralized Elements, on 18 September 2024.

The guidance addresses:

Trial design and conduct.

Remote clinical visits.

Local healthcare professionals.

Digital health technologies.

Sponsor and investigator responsibilities.

Informed consent and institutional review.

Investigational-product distribution.

Safety monitoring.

Software used in clinical trials.

Importantly, the FDA explains that ordinary regulatory requirements continue to apply to trials containing decentralized elements.

FDA+2

Official reference: FDA – Conducting Clinical Trials With Decentralized Elements (2024).

C. European Medicines Agency approach

The European Medicines Agency has developed recommendations addressing decentralized elements in clinical trials.

The European approach emphasizes maintaining participant safety, investigator oversight, data reliability and compliance with applicable clinical-trial requirements.

The broader European framework also involves the Clinical Trials Regulation (EU) No. 536/2014 and applicable data-protection law.

6. Accountability of different stakeholders

The most difficult issue in decentralized trial governance is determining who is legally responsible when harm results from a failure involving several independent actors.

These responsibilities are not necessarily exclusive. More than one party may incur liability for the same incident under the applicable law.

Example: Remote-monitoring failure

Suppose a participant enrolled in a decentralized cardiac trial uses a wearable monitoring device.

The device records a potentially dangerous heart rhythm. However:

The device fails to transmit the information.

The software does not generate an alert.

The investigator does not receive the information.

The participant suffers serious medical injury.

The legal investigation must determine:

Whether the device was appropriately validated.

Whether the software provider breached its contractual or legal duties.

Whether the sponsor established adequate monitoring procedures.

Whether the investigator complied with applicable supervision requirements.

Whether an emergency-response mechanism was available.

Whether the participant received adequate instructions.

This illustrates why decentralized trial governance requires a clear allocation of responsibilities and an effective incident-investigation mechanism.

7. Major legal challenges in decentralized trial governance

A. Jurisdictional conflicts

A decentralized trial may involve a sponsor located in the United States, an investigator in India, a technology provider in Europe and participants in multiple countries.

This creates questions concerning:

Which country's clinical-trial laws apply?

Which regulator can inspect trial records?

Where can participants bring compensation claims?

Which country's privacy laws govern participant data?

Which court has jurisdiction over disputes?

Cross-border research agreements should expressly address governing law, dispute resolution, regulatory cooperation and data-transfer responsibilities.

B. Algorithmic accountability

Artificial intelligence may be used to assess patient symptoms, identify adverse events and predict treatment outcomes.

Problems arise when algorithms generate incorrect recommendations or fail to detect dangerous clinical conditions.

Governance should require:

Human clinical supervision.

Algorithm validation.

Documented decision-making.

Bias assessment.

Explainability appropriate to the system's function.

Mechanisms for correcting inaccurate results.

An investigator should not blindly rely on automated outputs when professional assessment is required.

C. Participant exclusion and digital inequality

Decentralized trials can improve access for rural populations and people with mobility limitations. However, they may exclude participants who lack smartphones, internet access, digital literacy or reliable electricity.

This raises questions of equality and research justice.

Under Article 14 of the Indian Constitution, discriminatory exclusion may also raise constitutional concerns where State action is involved.

D. Compensation and liability

A participant may suffer an injury resulting from an investigational drug, an improperly performed home procedure or a defective monitoring device.

The legal framework must identify:

Whether the injury is trial-related.

Whether medical management was provided.

Whether statutory compensation is payable.

Whether professional negligence occurred.

Whether contractual or product-related liability also arises.

The Indian New Drugs and Clinical Trials Rules, 2019 are particularly important in this area.

E. Cybersecurity and confidentiality

Decentralized trials rely heavily on cloud-based infrastructure.

Cybersecurity failures may expose:

Genetic information.

Medical histories.

Neurological measurements.

Reproductive-health information.

Biometric information.

Medication records.

Sponsors must establish appropriate security, access control, incident response and data-retention arrangements.

8. Institutional governance model

A strong decentralized trial governance framework can be organized into five levels.

Decentralized Trial Governance Framework

Level 1 – Regulatory Governance

Government regulators, trial authorization, inspections and enforcement

Level 2 – Ethical Governance

Ethics Committees, informed consent and participant rights

Level 3 – Institutional Governance

Sponsors, investigators, healthcare providers and laboratories

Level 4 – Technological Governance

AI systems, software, wearable devices and digital records

Level 5 – Participant Accountability

Safety, privacy, compensation, complaints and withdrawal rights

This model ensures that decentralization does not result in fragmentation of legal responsibility.

9. Recommendations for strengthening decentralized trial governance in India

India should consider developing a more detailed regulatory framework addressing decentralized clinical research.

Important reforms include:

1. Specific DCT regulations: Establish clear regulatory standards for hybrid and fully decentralized clinical trials.

2. Digital consent standards: Develop reliable procedures for electronic identity verification, audiovisual consent and consent-record preservation.

3. Local healthcare provider accreditation: Establish appropriate qualification and training requirements for professionals performing delegated trial activities.

4. Remote safety monitoring: Require documented procedures for adverse-event alerts and emergency referrals.

5. Technology accountability: Establish standards for wearable-device validation, software reliability and algorithmic oversight.

6. Data protection: Strengthen safeguards for genetic, biometric and other sensitive research information under applicable privacy law.

7. Cross-border coordination: Improve cooperation between Indian regulators and foreign regulatory authorities.

8. Participant compensation: Ensure that participants can access medical treatment and applicable compensation without unnecessary procedural barriers.

9. Independent auditing: Establish risk-based audits of remote research activities, digital records and delegated responsibilities.

10. Accessible participation: Ensure that digital research methods do not discriminate against economically disadvantaged or technologically excluded populations.

10. Conclusion

Decentralized Trial Governance represents an important development in modern biotechnology, pharmaceutical research and healthcare regulation.

It shifts clinical research from a predominantly institution-centred model towards a distributed model involving participants, investigators, sponsors, technology companies, laboratories and local healthcare professionals.

However, decentralization must not mean decentralization of responsibility.

The principles established in Swasthya Adhikar Manch, Samira Kohli, Puttaswamy and other medical-law decisions provide important legal foundations for participant protection, informed consent, privacy and accountability.

The central legal principle is that technological convenience cannot override human dignity, patient autonomy, scientific integrity or regulatory responsibility.

A successful decentralized trial governance system must therefore combine regulatory supervision, independent ethical review, professional accountability, secure digital infrastructure and enforceable participant rights.

11. Important legal authorities for further research

Important academic qualification: The Indian judgments discussed above are not direct rulings on decentralized clinical trials. They are relevant judicial precedents whose legal principles can be applied to disputes arising from decentralized research. The FDA's 2024 guidance is regulatory guidance, not a judicial precedent, and is non-binding.

The next useful research topic is Decentralized Trial Governance Accountability Doctrine, examining the precise civil, regulatory and institutional liability of sponsors, investigators, technology providers and local healthcare professionals.